Xilio Therapeutics Inc (XLO) FinancialsXLOXilio Therapeutics Inc

Evaluating the bottom line, Xilio Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.68%, while the net margin is -34.09%. These profitability ratios, combined with a Return on Equity (ROE) of -55.03%, provide a clear picture of how effectively XLO converts its operational activities into shareholder value.

In the context of the broader market, XLO competes directly with industry leaders such as TLPH and CTOR. With a market capitalization of $56.72M, it holds a leading position in the sector. When comparing efficiency, XLO's gross margin of 100.00% stands against TLPH's N/A and CTOR's 67.07%. Such benchmarking helps identify whether Xilio Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Xilio has shown significant revenue growth, with Q2 2026 revenue reaching $18.7 million, a 131% increase year-over-year. The gross margin is consistently at 100%, reflecting strong operational efficiency despite net losses.